Identification of New GPCR Targets in NET Cell Lines Using Ligand Screening Abstract #624

Introduction: Although somatostatin analogs constitute an important part of current therapeutic strategies, both hypersecretion and proliferation of NETs cannot be controlled efficiently in many patients. Identifying and dissecting new molecular targets and regulatory pathways may help to improve diagnostic and therapeutic options for NET patients.
Aim(s): This study was focused on identifying new G protein-coupled receptor (GPCR) targets on neuroendocrine tumor cells, with special attention to peptide GPCRs and receptors for licenced drugs. Their role in NET cell signaling, secretion and proliferation was studied.
Materials and methods: A ligand screen involving 1,200 peptide and small-molecule ligands was carried out on six permanent cell lines derived from human NETs, among them BON and H727 cells. Dynamic mass redistribution, calcium and cAMP were measured to screen or confirm reactivities of ligands, including specific analogs or antagonists. Proliferation was measured using DAPI HCA or BrDU staining, secretion by ELISA assays.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Carsten Grötzinger

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture
Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez
#316 Utilization of Gene Network Graph Topology with Inference Relevance Analysis Delineates G Protein-coupled Receptor Pathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia
Introduction: Despite an increasing incidence, a paucity of biological information has led to major limitations in identification of plausible therapeutic targets for small intestinal neuroendocrine tumors (SINETs)
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients
Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tao Cui
#1467 iFiT: An Integrative Bioinformatics Platform for Biomarker and Target Discovery. A Case Study in Neuroendocrine Tumors
Introduction: iFiT (Ipsen Focused-on-new bIological enTities and biomarkers) is a Bioinformatics platform integrating systems biology functionalities together with semantic & logic-based artificial intelligence within a high-scale computing environment.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: PhD Sebastien Tourlet
Keywords: Targets iFiT
#2294 Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors
Introduction: Neuroendocrine tumours (NETs) have been found to overexpress somatostatin receptors (SSTRs), which led to the development of somatostatin analogs utilized for diagnostics and therapeutics. However, around 30% of all NETs do not respond to somatostatin based approaches, leading to an interest to find and characterize alternative cell surface targets.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger